If you have been reading about synaptic plasticity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
=== Phase 2b clinical trial – ABSSSI === Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections The study started February 2014 and announced completed enrollment 19 August 2014. Overall, 215 patients were randomized to one of three dosing regimens of brilacidin (single dose 0.6 mg/kg; single-dose 0.8 mg/kg; 1.2 mg/kg over 3 days) or 7 days of once daily daptomycin. finding that a single dose brilacidin was comparable to 7 days of daptomycin. The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of the ABSSSI lesion, relative to baseline, when observed 48–72 hours after the first dose of study drug, and no rescue antibiotics administered.
==== Lithium levels ==== According to Stahl's Prescriber's Guide, target concentrations for acute mania should be 1.0–1.5 mEq/L. 0.6–1.0 mEq/L for depression, and 0.7–1.0 mEq/L for long-term maintenance of bipolar disorder. In the elderly, lower doses and lower lithium levels (<0.6 mEq/L) are often adequate and advisable. The Maudsley and Ghaemi prescriber's guides recommend a slightly lower lithium level of 0.8–1.0 mmol/L for acute mania. For the maintenance treatment of bipolar disorder, the International Society for Bipolar Disorders (ISBD) and International Study Group on Lithium (ISGL) guidelines recommend lithium levels of 0.6–0.8 mmol/L. In the case of good response but poor tolerance, the guidelines recommend a level of 0.4–0.6 mmol/L. In the case of insufficient response but good tolerance, the guidelines recommend a level of 0.8–1.0 mmol/L. For the maintenance treatment of the elderly, the ISBD and ISGL guidelines recommend a more conservative approach of levels of 0.4–0.6 mmol/L, with the option to go up to 0.7 or 0.8 mmol/L at ages 65–79, and up to a maximum of 0.7 mmol/L over age 80. As a result of lithium's narrow therapeutic index, toxic effects can occur at serum concentrations close to therapeutic levels, necessitating close monitoring during treatment. Initially, levels are measured every 1–2 weeks until the desired serum concentration is achieved, then every 2–3 months for the first 6 months. Once stable, levels are measured every 6–12 months. Levels of 1.2–1.5 mmol/L are considered borderline toxic. Levels above 1.5 mmol/L are considered toxic.
== Medical uses == Bremelanotide is used for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Specifically, it is only recommended in those who have the condition without an underlying cause, such as medical, psychiatric, or relationship problems. Researchers have questioned the relevance and validity of the rating scales and outcomes on which bremelanotide was assessed, as well as the drug's effect sizes for these, concluding that benefits may only be modest. It should be used at least 45 minutes before anticipated sexual activity. Only one dose per 24 hours or no more than eight doses per month is recommended. It should be stopped after eight weeks if there is no improvement in sexual desire and associated distress.
Sources: en.wikipedia.org
== Production == The major industrial synthesis involves the reaction of sulfur trioxide and sulfur dichloride. This synthesis can be adapted to the laboratory by heating oleum to slowly distill the sulfur trioxide into a cooled flask of sulfur dichloride.
==== Psychosis ==== Cocaine has a similar potential to induce temporary psychosis with more than half of cocaine abusers reporting at least some psychotic symptoms at some point. Typical symptoms include paranoid delusions that they are being followed and that their drug use is being watched, accompanied by hallucinations that support the delusional beliefs. Delusional parasitosis with formication ('cocaine bugs') is also a fairly common symptom. Cocaine-induced psychosis shows sensitization toward the psychotic effects of the drug. This means that psychosis becomes more severe with repeated intermittent use.
HVEC's entry into high-energy research accelerators began in 1949 with its 4 MV Cosmotron particle injector. By 1951, HVEC had begun producing its single-ended CN series that became the first mass-produced research accelerators. The CN design was based on a vertical accelerator at MIT designed by John Trump. It employed resistor grading in both column and tube structure, field-shaping column hoops, and high-pressure insulating gas mixtures of nitrogen and carbon dioxide. Operating in a single stage at terminal voltages up to 6.5 megavolts, the 26 CN models manufactured by HVEC reliable platforms for light-ion nuclear physics experiments. However, fundamental physics questions, particularly the structure of heavier nuclei, demanded higher particle energies than a single-stage Van de Graaff accelerator could reach.
Produce traceability makes it possible to track produce from its point of origin to a retail location where it is purchased by consumers. Produce traceability is an important link in protecting public health since it allows health agencies to more quickly and accurately identify the source of contaminated fruit or vegetables believed to be the cause of an outbreak of foodborne illness, remove them from the marketplace, and communicate to the supply chain. Since many fruits and vegetables are eaten raw, the produce industry‚ from farmer to retailer, works diligently to protect these foods from contamination. Despite their best efforts, foreign matter can occasionally contaminate produce in the field or orchard, in packing or processing, in transit or storage. Controlled cold chains are frequently used. Because traceability systems can provide information on the source, location, movement and storage conditions of produce, they also allow growers, packers, processors and distributors to identify factors affecting quality and delivery. Beginning in 2008, an industry-led effort to enhance traceability throughout the entire produce supply chain was launched as the Produce Traceability Initiative.
Sources: en.wikipedia.org
A review of the UKPDS, Action to Control Cardiovascular Risk in Diabetes (ACCORD), Advance and Veterans Affairs Diabetes Trials (VADT) estimated that the risks of the main complications of diabetes (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and macrovascular disease) decreased by about 3% for every 1 mmol/mol decrease in HbA1c. However, a trial by ACCORD designed specifically to determine whether reducing HbA1c below 42 mmol/mol (6.0 DCCT %) using increased amounts of medication would reduce the rate of cardiovascular events found higher mortality with this intensive therapy, so much so that the trial was terminated 17 months early. Practitioners must consider patients' health, their risk of hypoglycemia, and their specific health risks when setting a target HbA1c level. Because patients are responsible for averting or responding to their own hypoglycemic episodes, their input and the doctors' assessments of the patients' self-care skills are also important. Persistent elevations in blood sugar (and, therefore, HbA1c) increase the risk of long-term vascular complications of diabetes, such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy (loss of sensation, especially in the feet), gangrene, and gastroparesis (slowed emptying of the stomach). Poor blood glucose control also increases the risk of short-term complications of surgery, such as poor wound healing.
and thus consists of three types of nuclei, which are supposed to be symmetric: a deuterium nucleus (actually a highly excited state of it), a nucleus with two protons, and a nucleus with two neutrons. These states are not stable.
== Packaging == Passive barrier packaging can often help control or extend shelf life by blocking the transmission of deleterious substances, like moisture or oxygen, across the barrier. Active packaging, on the other hand, employs the use of substances that scavenge, capture, or otherwise render harmless deleterious substances. When moisture content is a mechanism for product degradation, packaging with a low moisture vapor transmission rate and the use of desiccants help keep the moisture in the package within acceptable limits. When oxidation is the primary concern, packaging with a low oxygen transmission rate and the use of oxygen absorbers can help extend the shelf life. Produce and other products with respiration often require packaging with controlled barrier properties. The use of a modified atmosphere in the package can extend the shelf life for some products.
The UK provides the Operational Ration Pack, General Purpose. Packed inside a small cardboard box, each ration has enough retort-pouched and canned foods to feed one soldier for 24 hours. Seven menus (plus vegetarian and religious variants) provide two precooked meals (Breakfast and Main Meal) plus a midday snack. Example (Menu A) Breakfast: Hamburger and beans, Instant Porridge. All ration packs also contain Oatmeal Block, Fruit Biscuits, Biscuits Brown (a more compact alternative to bread), a sachet of instant soup and jam or yeast extract (a Marmite like spread) for a lunchtime snack, and chocolate (in the form of a specially made Yorkie bar which is flatter than civilian bars, or, more recently, a simple unbranded bar of milk chocolate), though this has been phased out with the introduction of the more recent multi-climate ration packs, and boiled sweets (hard candy) for snacking whilst on patrol, or in free time. Main Meal: Instant soup, Chicken with Mushroom and Pasta, Treacle Pudding. Each pack also contains instant coffee, tea bags, creamer, sugar, hot cocoa mix, beef/vegetable stock powder, lemon/orange powder or Lucozade electrolyte powder, matches, packet of tissues, chewing-gum, a small bottle of Tabasco sauce, and water purifying tablets. They sometimes also contain chicken and herb pâté. Also available are Kosher/Halal, Vegetarian, and Hindu/Sikh specific menus. Regardless of their contents, these ration packs are referred to as Rat-Packs or Compo (short for Composite Rations) by the soldiers who eat them.
It suggests that this level is mostly fixed by factors that are hereditary or determined early in life, implying that any change to well-being is only temporary and will eventually revert to the individual's baseline.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.